The future of the Johnson & Johnson's vaccine to be announced by the end of the day

NOW: The future of the Johnson & Johnson’s vaccine to be announced by the end of the day
NEXT:

CNN -- The future of the Johnson and Johnson's COVID-19 vaccine is in the hands of CDC advisers today.

A CDC advisory panel is meeting this morning to discuss the future of the Johnson and Johnson one-dose COVID-19 vaccine at 11 a.m.

In Europe, they've already started using the shot again amid clotting concerns but with a warning attached.

And, concerns arise if the U.S will follow the suit.

The real question is if it's found to be safe, could that encourage more people to get the shot?

But, ongoing clotting concerns are still at the top of many American’s minds causing vaccine hesitancy.

In fact, thousands of vaccination appointments are being left unfilled.

That means some vaccination sites nationwide are now having to close their doors.

The daily average number of shots being administered now sits at under 3 million, which is the lowest the U.S. has seen in three weeks.

Experts say the possible complications of the vaccine are fueling fears.

The number of women experiencing rare blood clots rising to seven with a second death reported in Oregon on Thursday.

Officials say the patient was in her fifties who developed symptoms and low platelets two weeks after getting vaccinated.

Meanwhile, another 18-year-old woman in Nevada is suffering from seizures and has undergone three brain surgeries related to blood clotting.

However, health officials say the benefits still outweigh the possible risks.

"We need to make a decision quickly and I'm really hopeful that we'll be able to use the vaccine soon,” said Dr. Rochelle Walensky, CDC director.

"Vaccines don't equal vaccination. So we got to get people to vaccination clinics, to get them to talk to their doctors to answer their questions and ultimately get vaccinated. That's how we are going to protect ourselves and our families,” said Vivek Murthy, surgeon general.

Share this article: